| Field | Specification |
|---|---|
| Target | |
| Alternative names | H 16868 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C17H19N3O3S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Omeprazole, also known as H 16868, is an orally active H+,K+-ATPase inhibitor and proton pump inhibitor that competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. It inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. In pancreatic cancer cells, it inhibits proliferation and induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, while modulating lysosomal transport and reducing inflammatory cytokines. It also alters small intestinal morphology and magnesium absorption, induces gastric mucosa morphologic changes, and has neuroprotective and antibacterial effects[1][2][3][4][5]. It is supplied as a white to off-white solid (C17H19N3O3S, MW 345.42) at 99.96% purity.
Physical & Chemical Properties
| CAS Number | 73590-58-6 |
|---|---|
| Molecular Formula | C17H19N3O3S |
| Molecular Weight | 345.42 g/mol |
| Purity | 99.96% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=S(C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C |
| Target | CYP2C19, CYP2C9, CYP3A4, LC3-I, LC3-II, IL-1β, IL-6 |
| Signaling Pathway | Membrane Transporter/Ion Channel; Anti-infection; Metabolic Enzyme/Protease; Apoptosis; Autophagy; Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 100 mg/mL (289.50 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: < 0.1 mg/mL (insoluble) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
Activity & Target
[1][2][5]
|
CYP2C19 2.4-6.2 μM (Ki) |
CYP2C9 16.4 μM (Ki) |
CYP3A4 41.9 μM (Ki) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[6]. Jonkers D, et al. Omeprazole inhibis growth of Gram-positive and Gram-negative bacteria including Helicobacter pylori in vitro[J]. Journal of Antimicrobial Chemotherapy, 1996, 37(1): 145-150.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (289.50 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | < 0.1 mg/mL | insoluble |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (7.24 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (7.24 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (7.24 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
In pooled human liver microsomes, Omeprazole (15 min) competitively inhibits CYP2C9 activity, with a Ki of 16.4 μM[1]. Omeprazole (20 min) also competitively blocks CYP2C19 activity in pooled human liver microsomes, with a Ki of 2.4-6.2 μM[1]. In pooled human liver microsomes, Omeprazole (15 min) does not significantly inhibit CYP2D6 activity (IC50 >200 μM)[1]. Competitive inhibition of CYP3A4 activity in pooled human liver microsomes is also seen with Omeprazole (15 min), with a Ki of 41.9 μM[1]. Omeprazole (0-200 μg/mL; 4 days) dose-dependently inhibits proliferation of the human pancreatic cancer cell lines MiaPaCa-2, ASPC-1, Panc-1, Colo357, PancTu-1, and Panc89, with IC50 values from 9.1 to 42.4 μg/mL[2]. At 80 μg/mL (30 min-24), Omeprazole does not cause consistent intralysosomal pH changes in the human pancreatic cancer cell lines MiaPaCa-2 and ASPC-1; after 24 hours of incubation at 80 μg/mL, however, acidity increases in ASPC-1 cells and decreases in MiaPaCa-2 cells[2]. In MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, early autophagic markers (phagophores and autophagosomes) accumulate with Omeprazole (80-160 μg/mL; 24 h), and apoptosis is induced in ASPC-1 cells[2]. In MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, Omeprazole (80 μg/mL; 24 h) builds up inside the cells and alters fatty acid and phospholipid metabolism[2]. In MiaPaCa-2 human pancreatic cancer cells, Omeprazole (80 μg/mL; 24 h) changes the distribution of lysosomal markers and lowers expression of a Golgi complex marker, indicating disruption of the lysosomal transport pathway without accumulation in lysosomes or the Golgi complex[2]. At 40-160 μg/mL for 24 h, Omeprazole induces autophagy dose-dependently, raising LC3-I and LC3-II levels and impairing autophagosome turnover in the human pancreatic cancer cell lines MiaPaCa-2 and ASPC-1[2]. Omeprazole (80 μg/mL; 6-24 h) changes gene expression in ASPC-1 and MiaPaCa-2 human pancreatic cancer cell lines; in ASPC-1 cells, bad and survivin are downregulated and mdr-1 is upregulated[2]. In MiaPaCa-2 and ASPC-1 human pancreatic cancer cell lines, Omeprazole (80 μg/mL; 24 h) activates autophagy through upregulation of Atg12, and in ASPC-1 cells it also upregulates pro-apoptotic Puma[2]. Omeprazole gives rise to sulfone, sulfite and hydroxy-omeprazole, which can produce additional oxidative damage[3]. Omeprazole has toxicogenic effects on Allium cepa plant cells, Saccharomyces cerevisiae, and murine Sarcoma 180 cells[3]. Omeprazole (200-300 mg/L) inhibits E.faecalis dose-dependently at time zero[6]. At both time zero and 2 h, Omeprazole (200 mg/L) inhibits S. aureus[6].
Cell Proliferation Assay[2]
| Cell Line | MiaPaCa-2, ASPC-1, Panc-1, Colo357, PancTu-1, Panc89 |
|---|---|
| Concentration | 0-200 μg/mL |
| Incubation Time | 4 days |
| Result | Inhibited cell proliferation in a dose-dependent manner, with IC50 values of 42.4 μg/mL (MiaPaCa-2), 11.2 μg/mL (ASPC-1), 31.8 μg/mL (Panc-1), 26.4 μg/mL (Colo357), 20.7 μg/mL (PancTu-1), and 9.1 μg/mL (Panc89). Showed a mild growth-stimulatory hormetic effect in some cell lines at low concentrations. Mitigated the hormetic growth stimulation induced by low-dose 5-fluorouracil in ASPC-1, Panc-1, and PancTu-1 cells. Showed additive effects with low-dose 5-fluorouracil in MiaPaCa-2 cells. Showed antagonistic effects with low-dose 5-fluorouracil in Panc89 cells. Showed additive or antagonistic interactions with gemcitabine. |
Western Blot Analysis[2]
| Cell Line | MiaPaCa-2, ASPC-1 |
|---|---|
| Concentration | 40 μg/mL, 80 μg/mL, 160 μg/mL |
| Incubation Time | 24 h |
| Result | Caused a dose-dependent marked elevation of LC3-I and LC3-II fractions in both cell lines. |
Real Time qPCR[2]
| Cell Line | ASPC-1, MiaPaCa-2 |
|---|---|
| Concentration | 80 μg/mL |
| Incubation Time | 6 h, 12 h, 18 h, 24 h |
| Result | Significantly downregulated pro-apoptotic bad mRNA in ASPC-1 cells after 24 hours. Significantly downregulated pro-survival survivin mRNA in ASPC-1 cells after 24 hours. Significantly upregulated mdr-1 mRNA in ASPC-1 cells after 24 hours. Did not significantly alter mdr-1 mRNA expression in MiaPaCa-2 cells. |
In Vivo
In male Sprague-Dawley rats, Omeprazole (20 mg/kg; s.c.; daily; 12-24 weeks) causes small intestinal inflammation, villous atrophy, narrowing of tight junctions, and systemic magnesium deficiency accompanied by hypomagnesemia[4]. In Rattus norvegicus, Omeprazole prevents peripheral neuropathy induced by Oxaliplatin[5]. In sciatic nerve-ligated mice, Omeprazole lowers the levels of the inflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6[5].
| Animal Model | Sprague-Dawley (male, 9 weeks old at study initiation)[4] |
|---|---|
| Dosage | 20 mg/kg |
| Administration | s.c.; daily; 12 weeks; 24 weeks |
| Result | Decreased villous length and mucosa-to-serosa amplification ratio in duodenum, jejunum, and ileum compared to controls. Increased duodenal crypt depth and width compared to controls. Reduced the number of secretory granules per Paneth cell in duodenum, jejunum, and ileum after 24 weeks of treatment compared to controls. Increased CD3+ intraepithelial lymphocytes and CD8+ intraepithelial lymphocytes compared to controls. Reduced plasma Mg2+ levels to 0.64 mM after 12 weeks and 0.57 mM after 24 weeks compared to control level of 1.07 mmol/L. Reduced urinary Mg2+ excretion compared to controls. Increased fecal Mg2+ excretion after 24 weeks of treatment compared to controls. Reduced bone and muscle Mg2+ content. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. Cell Metab 2024 Aug 6;36(8):1806-1822.e11. PMID: 38897198
Gut-microbiota-derived indole sulfate promotes heart failure in chronic kidney disease. Cell Host Microbe 2025 Oct 8;33(10):1715-1730.e5. PMID: 40961933
Sequence-based drug design as a concept in computational drug design. Nat Commun 2023 Jul 14;14(1):4217. PMID: 37452028
CCR7 Mediated Mimetic Dendritic Cell Vaccine Homing in Lymph Node for Head and Neck Squamous Cell Carcinoma Therapy. Adv Sci (Weinh) 2023 Jun;10(17):e2207017. PMID: 37092579
Expanded applications of omeprazole: Synergistic reversal of colistin resistance in Acinetobacter baumannii. Int J Antimicrob Agents 2025 Oct 8;66(6):107639. PMID: 41072861
Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants. Sci Rep 2026 Mar 20;16(1):14300. PMID: 41862552
Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS. J Pharm Biomed Anal 2026 Jan 1:267:117128. PMID: 40865303
Vitamin D3 in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway. Tissue Cell 2026 Apr 22:102:103551. PMID: 42033901
Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method. Br J Clin Pharmacol 2026 May 31. PMID: 42219154
Notable drug-drug interaction between omeprazole and voriconazole in CYP2C19 *1 and *2 (rs4244285, 681G>A) alleles in vitro. Xenobiotica 2024 Oct;54(10):847-854. PMID: 39445918
